TABLE 3.
Anticoagulation on admission to intensive care unit by cohort and increases in anticoagulation intensity following intensive care unit admission by cohort
| COVID‐19 N = 443 |
ORVI N = 387 |
p | |
|---|---|---|---|
| Anticoagulation intensity on admission to ICU, N (%) | |||
| Standard prophylactic | 216 (48.8) | 252 (65.1) | <.001 |
| Intermediate | 84 (19.0) | 8 (2.1) | |
| Treatment | 127 (28.7) | 104 (26.9) | |
| Home warfarin held because of therapeutic/supratherapeutic INR | 4 (1.0) | 4 (1.0) | |
| Nonea | 12 (2.7) | 19 (4.9) | |
| Anticoagulation intensity increase following ICU admission, N (%) | |||
| Yes | 189 (59.8) | 73 (25.8) | <.001 |
| No | 127 (40.1) | 210 (74.2) | |
| Ineligible (already on therapeutic intensity) | 127 (28.7) | 104 (26.9) | |
| Reason for increase in anticoagulation intensity, N (%)b | |||
| Suspected thrombosis | 15 (7.9) | 5 (5.5) | <.001 |
| Confirmed thrombosis | 27 (14.3) | 12 (16.4) | |
| Deterioration in clinical status | 91 (48.2) | 4 (5.5) | |
| Atrial fibrillation or flutter | 14 (7.4) | 19 (26.0) | |
| Initiation of ECMO | 1 (0.53) | 8 (11.0) | |
| Concern for heparin‐induced thrombocytopenia | 1 (0.53) | 1 (1.4) | |
| Elevated D‐dimer/concern for hypercoagulability | 12 (6.4) | 0 (0) | |
| Institutional guidelines | 3 (1.6) | 0 (0) | |
| Contraindication to anticoagulation resolvedc | 6 (3.2) | 7 (9.6) | |
| Other/unknown | 19 (10.6) | 17 (23.2) | |
Abbreviations: COVID‐19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenator; ICU, intensive care unit; INR, international normalized ratio; ORVI, other respiratory virus infection.
Patients were not on anticoagulation on day of admission to the ICU. All patients eventually received anticoagulation at a later date.
If patient had increase in anticoagulation intensity, the reason for anticoagulation intensity increase was reflected in clinical progress notes.
Number of patients who had anticoagulation initially held because of contraindication such as bleeding, severe thrombocytopenia, or elevated INR and then resumed anticoagulation when contraindication resolved.